Nottingham, United Kingdom

Jonathan Shannon

This inventor holds 22 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Inflazome Limited, Cellcentric Limited, Otsuka Pharmaceutical Company, Limited. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Shannon. Retrieved from https://idiyas.com/inventor/jonathan-shannon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 22 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2019-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Benzolactam Compounds
Protein Kinase Inhibitors
Sulfonamide Compounds
NLRP3 Inhibitors
Sulfonylureas
Sulfonylthioureas
Carboxamide Compounds
Pharmaceutical Chemistry
Drug Development
Chemical Inhibitors
Medicinal Chemistry
22 patents (USPTO):Explore Patents

Title: The Innovative Mind of Jonathan Shannon

Introduction

Jonathan Shannon is a prolific inventor based in Nottingham, GB, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 20 patents, he has been at the forefront of developing innovative compounds aimed at treating various medical disorders. His work exemplifies the intersection of creativity and science, making him a notable figure in the realm of medical inventions.

Latest Patents

Among his latest patents, two stand out for their potential impact on medical treatments. The first patent, concerning **sulfonamide carboxamide compounds**, relates to sulfonylureas and sulfonylthioureas that feature a 5-membered heteroaryl group. This invention includes salts, solvates, and prodrugs of such compounds, highlighting their pharmaceutical applications in treating and preventing disorders by inhibiting NLRP. The second patent for **sulfonamideurea compounds** describes compounds of a specific formula where the configurations may form cyclic groups, again focusing on their medicinal use and potential in inhibiting NLRP3. Both patents showcase Jonathan's dedication to advancing therapeutic options for complex medical conditions.

Career Highlights

Jonathan’s career has been marked by his impactful work at various companies, including Inflazome Limited and Cellcentric Limited. His roles in these organizations have allowed him to collaborate with other esteemed professionals and contribute meaningfully to innovative projects.

Collaborations

Throughout his career, Jonathan has had the opportunity to work alongside talented individuals, including David Miller and Angus Macleod. These collaborations have fostered a creative environment, significantly influencing the progression of his inventions and patents.

Conclusion

Jonathan Shannon's journey as an inventor illustrates the power of innovation in addressing medical challenges. With an impressive body of work and ongoing collaborations, he continues to pave the way for future breakthroughs in pharmaceutical technology. His contributions are vital not only to the scientific community but also to enhancing patient care across the globe.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…